

PTO/SB/08A (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

ontrol number.				Complete if Known		
Substitute for form 1449A/PTO		Application Number	10/073,065			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	February 12, 2002			
STATEME	NT BY AP	PLIC	ANI		First Named Inventor	Shyam Mohapatra
(us	e as many shee	ls as nec	essary)		Art Unit	1648
					Examiner Name	Myron G. Hill
Sheet	1	of		2	Attorney Docket Number	USF-T156X

			U.S. PATENT DO	OCUMENIS	
Examiner	Cite	Document Number Number - Kind Code <sup>2</sup> (if	Publication Date	Name of Patentee or Applicant	Pages, Columns, Lines, Where Relevant Passages or Relevant
Initials*	No. 1	known)	MM-DD-YYYY	of Cited Document	Figures Appear
МН	U1	US-6,900,299 B1	05-31-2005	Mohapatra et al.	All
Ī	U2	US-6,489,306 B2	12-03-2002	Mohapatra et al.	All
	U3	US-2005/0272650 A1	12-08-2005	Mohapatra	All
	U4	US-2005/0266093 A1	12-01-2005	Mohapatra	All
	U5	US-2005/0159385 A1	07-21-2005	Mohapatra	All
	U6	US-2003/0198624 A1	10-23-2003	Mohapatra et al.	All
V	U7	US-2001/0006951 A1	07-05-2001	Mohapatra et al.	All
	U	US-			
	U	US-			

	FOREIGN PATENT DOCUMENTS							
		Foreign Patent Document	Dublication Date	Name of Patentee or	Pages, Columns, Lines,			
Examiner Initials*	Cite No. 1	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	٣		
	F1 -				) 			
	F2					<u> </u>		
	F3		.· <u>.</u>			ļ		
	F4					<b>!</b>		
	F5					<u> </u>		
	F6					<u> </u>		
	F7							

Examiner	Date	
Signature /Myron Hill/	Considered	05/01/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP901.04. Enter Office that issued the document, by the two-letter code (MPO Standard T.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need essistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

FEB J 4 700K

Sheet

PTO/SB/08B (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork-Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

2

Substitute for form 1449B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Complete if Known

Application Number 10/073,065

Filing Date February 12, 2002

First Named Inventor Shyam Mohapatra

Group Art Unit 1648

Examiner Name Myron G. Hill

Attorney Docket Number USF-T156X

		NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
MH R1		BARENDS, M. et al. "Timing of infection and prior immunization with respiratory syncytial virus (RSV) in RSV-enhanced allergic inflammation" J Infections Diseases, 2004, 189:1866-1872.	
	R2	BIANCO, I. et al. "Chitosan-induced phospholipase A <sub>2</sub> activation and arachidonic acid mobilization in P388D <sub>1</sub> macrophages" FEBS Letters, 2000, 466:292-294.	
	R3	Centers for Disease Control and Prevention, 1999, Update: Respiratory syncytial virus activity—United States, 1998-1999 season.	
	R4	KNEYBER, M. et al. "Treatment and prevention of respiratory syncytial virus infection" Eur. J. Pediatr, 2000, 159:399-411.	
	R5	NICHOLAS, J.A. et al. "Cytolytic T-lymphocyte responses to respiratory syncytial virus: Effector cell phenotype and target proteins" J. Virology, 1990, 64:4232-4241.	
	R6	OPENSHAW, P. and TREGONING, J. "Immune responses and disease enhancement during respiratory syncytial virus infection" Clin Mirobiol Rev, 2005, 18:541-555.	
	R7	OPENSHAW, P. et al. "Immunopathogenesis of vaccine-enhanced RSV disease" Vaccine, 2002, 20:S27-S31.	
	R8	OTTERLEI, M. et al. "Characterization of binding and TNF-alpha-inducing ability of chitosans on monocytes: the involvement of CD14" Vaccine, 1994, 12:825-832, abstract.	
	R9	PIEDRA, P. "Clinical experience with respiratory syncytial virus vaccines" Pediatr Infect Dis J, 2003, 22:S94-S99.	
V	R10	RICHARDSON, S. et al. "Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA" Intn'l J Pharmaceutics, 1999, 178:231-243.	
	R		
	R		
	R		T

Examiner	/Myron Hill/	Date	05/01/2006
Signature	///	Considered	05/01/2000

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

ons are required to respond to a collection of information unless it contains a valid OMB Under the Paperwork Reduction Act of control number.

· Complete if Known Substitute for form 1449A/PTO **Application Number** 10/073,065 INFORMATION DISCLOSURE **Filing Date** February 12, 2002 STATEMENT BY APPLICANT **First Named Inventor** Shyam Mohapatra (use as many sheets as necessary) Art Unit 1648 **Examiner Name** Myron G. Hill **Attorney Docket Number** of **USF-T156X** 2 Sheet

			U.S. PATENT DO	OCUMENTS .	·
Evaminas	Cito	Document Number	Publication Date	Name of Patentee or Applicant	Pages, Columns, Lines, Where
Examiner Cite Initials* No. 1		Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	of Cited Document	Relevant Passages or Relevant Figures Appear
	U1	US-			
	U2	US-			
	U3	US-		•	
	U4_	US-			
	U5	US-	<u></u>		
	U6	US-			·
	U7	US-			
	U8	US-			
	U9	US-			

<u></u>		FOREIGN	PATENT DOCL	JMENTS		
	0"-	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	
Examiner Initials*	Cite No. '	Country Code 3 - Number 4 - Kind Code5 (if known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	r
MH	F1	WO 03/028759 A1	04-10-2003	Univ. of South Florida	All	
MH	F2	WO 02/34287 A2	05-02-2002	Pharmexa A/S	All	<u> </u>
MH	F3	WO 99/36089 A1	07-22-1999	Johns Hopkins Univ.	All	<u> </u>
MH	F4	WO 97/20576 A1	06-12-1997	Danbiosyst UK Lmtd.	All	
	F					<u> </u>
	F			•		<u> </u>
	F			•		<u> </u>

Examiner Date Considered 05/04/2006				
1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -	Examiner		Date	•
	Signature	/Myron Hill/	Considered	05/04/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language

Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

control number. Complete if Known Substitute for form 1449B/PTO 10/073,065 **Application Number** INFORMATION DISCLOSURE February 12, 2002 **Filing Date** STATEMENT BY APPLICANT **First Named Inventor** Shyam Mohapatra **Group Art Unit** 1648 (use as many sheets as necessary) **Examiner Name** Myron G. Hill USF-T156X **Attorney Docket Number** 2 of Sheet

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
МН	R1	BIVAS-BENITA, M. et al. "Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis" Vaccine, 2004, 22:1609-1615.	
МН	R2	DOW, S. et al. "Systemic and local interferon y gene delivery to the lungs for treatment of allergen-induced airway hyperresponsiveness in mice" <i>Human Gene Therapy</i> , 1999, 10:1905-1914.	•.
МН	R3	HAMAJIMA, K. et al. "Chitin micro-particles (CMP): A useful adjuvant for inducing viral specific immunity when delivered intranasally with an HIV-DNA vaccine" Viral Immunology, 2003, 16:541-547.	·
MH	R4	HELLERMAN, G. et al. "Chitosan IFN-gamma-gene nanosphere (CIN) therapy for allergic asthma: Modulation of specific T-cell and dendritic cell responses" J. Allergy Clin. Immunol., 2003, 111(2):S265, abstract no. 791.	
MH	R5	KONG, X. et al. "Chitosan IFN-gamma-gene nanoparticle (CIN) therapy for allergic asthma in mice involves STAT4 signaling pathway" J. Allergy Clin. Immunol., 2003, 111(2):S354, abstract no. 1144.	
МН	R6	KUMAR, M. et al. "Role of mucosal IFN-γ gene transfer on allergic sensitization and RSV infection" J. Allergy Clin. Immunol., 2002, 109(1):S4, abstract no. 78.	,·*.
	R		
	R		
	R		
	R		
	R		
	R		
	R	•	

		I Data	
Examiner	/Manager 17-17-1	Date	05/04/0006
Signature	/Myron Hill/	' Considered	05/04/2006
Colginature			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.